Subodh Verma

MD, PhD, FRCSC, FAHA

Scientist

Biography

Please note: Dr. Verma will not take students in summer.

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.

 

Recent Publications

  1. Hibino, M, Pandey, A, Chan, V, Mazer, CD, Dhingra, NK, Bonneau, C et al.. Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 months in a Randomized Trial. Can J Cardiol. 2022; :. doi: 10.1016/j.cjca.2022.01.013. PubMed PMID:35074417 .
  2. Rai, A, Connelly, KA, Verma, S, Mazer, CD, Teoh, H, Ng, MY et al.. Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. Acta Diabetol. 2022; :. doi: 10.1007/s00592-021-01823-6. PubMed PMID:35061101 .
  3. Cosentino, F, Bhatt, DL, Marx, N, Verma, S. The year in cardiovascular medicine 2021: diabetes and metabolic disorders. Eur Heart J. 2022; :. doi: 10.1093/eurheartj/ehab876. PubMed PMID:34974614 .
  4. Docherty, KF, Ogunniyi, MO, Anand, IS, Desai, AS, Diez, M, Howlett, JG et al.. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2022;10 (1):52-64. doi: 10.1016/j.jchf.2021.08.006. PubMed PMID:34969498 .
  5. Kosiborod, MN, Esterline, R, Oscarsson, J, Gasparyan, SB, Furtado, RHM, Verma, S et al.. Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply. Lancet Diabetes Endocrinol. 2021; :. doi: 10.1016/S2213-8587(21)00326-0. PubMed PMID:34921753 PubMed Central PMC8673873.
  6. Hibino, M, Dhingra, NK, Verma, R, Puar, P, Verma, S, Yanagawa, B et al.. Surgical Treatment for Gerbode Defect Caused by Infective Endocarditis. J Invasive Cardiol. 2021;33 (12):E1009. . PubMed PMID:34866055 .
  7. Verma, S, Dhingra, NK, Butler, J, Anker, SD, Ferreira, JP, Filippatos, G et al.. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022;10 (1):35-45. doi: 10.1016/S2213-8587(21)00292-8. PubMed PMID:34861154 .
  8. Hess, DA, Verma, S, Bhatt, D, Bakbak, E, Terenzi, DC, Puar, P et al.. Vascular repair and regeneration in cardiometabolic diseases. Eur Heart J. 2021; :. doi: 10.1093/eurheartj/ehab758. PubMed PMID:34849704 .
  9. Hibino, M, Yanagawa, B, Pandey, AK, Verma, S. Ambient temperature and aortic dissection: do pipes burst in freezing weather?. Eur Heart J. 2022;43 (3):236-238. doi: 10.1093/eurheartj/ehab792. PubMed PMID:34849698 .
  10. Butler, J, Filippatos, G, Jamal Siddiqi, T, Brueckmann, M, Böhm, M, Chopra, VK et al.. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation. 2022;145 (3):184-193. doi: 10.1161/CIRCULATIONAHA.121.057812. PubMed PMID:34779658 PubMed Central PMC8763045.
Search PubMed

Affiliations & Other Activities

  • Cardiac Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor of Surgery and Pharmacology & Toxicology, University of Toronto
  • Canada Research Chair in Cardiovascular Surgery
X